

AbbVie Inc., April 28, 2021 ABBV.N Biotechnology & Drugs

Academic – Research Team Karolos Agious George Mavridis

Key Statistics (USD)			
Price	111.44		
Market Cap	196.673 B		
Enterprise Value	274.18 B		
PEG	-		
52 weeks high	113.41		
52 weeks low	79.11		
Beta (5Y-monthly)	0.81		
Dividend yield %	4.67		
EPS (TTM)	2.71		
DPS	5.20		
One year stock performance	33.04%		

Growth Rates	Company	Sector
Revenue (Q/Q last year)	59.21%	9.32%
Net earnings (YTD/YTD last year)	-41.90%	-1.75%
Net earnings (Q/Q last year)	-99.28%	-20.66%

Margins	Company	Sector
Gross Profit	66.69%	61.75%
margin		
EBITDA margin	-	-
EBT margin	7.42%	11.77%
Net Profit margin	10.09%	9.34%
Gross Profit	73.81%	62.35%
margin		
(5Y average)		
EBT margin	19.70%	14.32%
(5Y average)		

Key Ratios	Company	Sector
Current Ratio	0.84	1.46
Quick Ratio	0.73	1.11
Cash Ratio	-	-
ROE	185.77	10.39
ROA	3.86	5.26
ROC	4.73	5.67
D/E	5.93	0.75

Valuation Metrics	Company	Sector (median)
P/E (NTM)	8.64	-3.90
P/E (TTM)	40.90	20.91
P/B (TTM)	15.04	4.53
P/Sales (TTM)	4.29	32.13

Firm's Brief Description.

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).

Sector Overview

- The global biotechnology market size was valued at USD 752.88 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 15.83% from 2021 to 2028.
- The US global personalised medicine market is forecast to reach \$2.4 trillion by 2022 at a CAGR of 11.8% – more than double the projected 5.2% annual growth for the overall health care sector.
- The virtual healthcare market is expected to reach revenues over \$3.5 billion by 2022 with a CAGR of 49.8 percent during the forecast period.

Fundamental Analysis

AbbVie Inc. stock performance during the COVID-19 period rose by 33.04%. Considering the last 12 months, the company outperformed its competitors on revenue growth while underperformed on net earnings. Moreover, gross profit and net profit margin of 66.69 % & 10.09% are higher than the sector average which are 61.75% and 9.34% respectively. Following, the same pattern for the 5-year averages as well. Furthermore, the company with a Return on Equity (ROE) ratio of 185.77% strongly outperforms the sector's average of 10.39%. On the other side, the Return on Assets (ROA) ratio of 3.86% and Return on Capital (ROC) ratio of 4.73% are a bit lower than the sector's average (5.26 and 5.67 correspondingly). Finally, ABBV has a high dividend yield of 4.67% and a higher than the sector's median P/E ratio for the next 12 months and below 10, indicating an undervalued stock.

Target Price (1 year forward): 122.17 \$



AbbVie Inc., April 28, 2021 ABBV.N Biotechnology & Drugs

Academic – Research Team Karolos Agious George Mavridis

DISCLAIMER

THE FINANCE CLUB OF UNIVERSITY OF MACEDONIA, THESSALONIKI, GREECE

The Finance Club of University of Macedonia - www.financeclub.gr is an independent non-profitable student organization founded by students of the University of Macedonia, Greece (UoM - www.uom.gr) that aims to build strong relations between the market and the University. Though based in the University of Macedonia, it also operates via associates in Aristotle University of Thessaloniki, Greece and other institutions. The Club's goal is to give its members the chance to view the market in a more practical approach rather than solely relying on the abstract knowledge offered by the university. In order to achieve this goal, the Club organizes various events like conferences, workshops and seminars. Moreover, its members are able to cooperate with companies by taking up real case projects to work on along with the managers of the associated companies. In addition, the Club is trying to build and expand its network among students, market professionals and professors therefore giving its members a very broad pool of potential partners and employers.

This report has been compiled by the authors mentioned above and published by them via the Finance Club UoM site and many other platforms. The club confirms that the authors are active members at the time this article is published but emphasizes the fact that opinions and views given by the authors in this article are their own views. Finance Club UoM takes no responsibility for the completeness or correctness of information provided. No investment advice is given with the text above and the reader should not take any financial position based on the information published in this article. The Club recommends extensive research by the reader before investing in any financial asset. General this report may be based on the information extracted from various sources including but not limited to various companies' and statistical agencies' websites, online portals, third-party research, annual reports etc. No representation or warranty of any kind is or may be made with respect to the accuracy or completeness of, and no representation or warranty should be inferred from, any projections or futuristic statement contained herein or any underlying assumptions. This article may include descriptions, statements, estimates and projections/futuristic statements with respect to current and anticipated performance of the underlying. Such statements, estimates and projections reflect various assumptions and best estimates made by the participants concerning anticipated results, whose assumptions and estimates may or may not prove to be accurate or correct. There are no assurances whatsoever that any statements, estimates or projections contained in this article, including without limitation any financial or business projections, accurately present in all material respects the underlying's financial and/or business position as of the respective dates specified and the results of its operations for any respective periods indicated. No copyright or trademark infringement is intended in any form.

© Copyright 2020. Finance Club UoM